Company Description
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
The company’s lead candidate is FXR314, which is phase 2/3 clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus on non-alcoholic steatohepatitis and primary biliary cholangitis.
It has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters.
The company was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Keith E. Murphy |
Contact Details
Address: 11555 Sorrento Valley Road, Suite 100 San Diego, California 92121 United States | |
| Phone | 858-224-1000 |
| Website | organovo.com |
Stock Details
| Ticker Symbol | ONVO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001497253 |
| CUSIP Number | 68620A203 |
| ISIN Number | US68620A2033 |
| Employer ID | 27-1488943 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Keith E. Murphy | Company Secretary and Executive Chairman |
| Vaidehi Joshi | Director of Discovery Biology and Director |
| Thomas P. Hess CPA, MBA | President and Chief Financial Officer |
| Dr. Curtis M. Tyree Ph.D. | Senior Vice President of Strategy and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | 10-K | Annual Report |
| May 14, 2024 | 424B4 | Prospectus |
| May 13, 2024 | 8-K | Current Report |
| May 10, 2024 | 424B4 | Prospectus |
| May 8, 2024 | EFFECT | Notice of Effectiveness |
| May 1, 2024 | 8-K | Current Report |
| Apr 30, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 23, 2024 | 8-K | Current Report |
| Apr 17, 2024 | UPLOAD | Filing |
| Apr 12, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |